Abstract
Passive immunization with monoclonal antibodies (MAbs) has been shown to prevent a wide variety of diseases. Currently, there are no MAb products that are licensed for use for immunotherapy or immunoprophylaxis against infection by HIV. However, there are several rational arguments that can be advanced for the use of a passive immunization approaches for counteracting HIV much as for other diseases especially with respect to mother-to-child transmission (MTCT) of HIV and immediate post-exposure situations. Several arguments questioning the feasibility of the approach based on availability of effective drugs, high cost of production and distribution of the MAbs among others, also get raised. It seems that the field now is looking at some promising MAbs as well as several alternate ways to manufacture antibodies and which hopefully may positively affect cost-related issues. This summary of a workshop held to assess the role of MAbs in the treatment and prevention of HIV/AIDS provides a fairly comprehensive analysis of the usefulness of MAb technology for future HIV/AIDS research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
